Current Report Filing (8-k)
February 20 2018 - 5:33AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): February 20, 2018
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
2
nd
Ben Gurion Street, Ramat Gan, Israel
|
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: 972 (0) 72-260-8004
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
February 18, 2018, OWC Pharmaceutical Research Corp., OTCQB: OWCP (the “Registrant”), appointed Dr. Oron Yacoby
Zeevi as its Chief Scientific Officer (CSO). Dr. Yehuda Baruch, who served as the Registrant’s CSO will now serve as Chief Medical and Regulatory Officer of the Registrant.
Dr. Oron Yacoby Zeevi,
age 57, Chief Scientific Officer
: Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both
private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq:
NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders
as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure,
she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented
innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC,
early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards
development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology
and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine
from the Hebrew University of Jerusalem
Item
9.01 Financial Statements and Exhibits.
(a)
The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated
by reference is identified by a parenthetical reference to the SEC filing that included such document.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OWC
Pharmaceutical Research Corp.
|
|
|
|
|
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
|
Date:
February 20, 2018
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Apr 2024 to May 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about OWC Pharmaceuticals Research Corporation (CE) (OTCMarkets): 0 recent articles
More Owc Pharmaceutical Research Corp. News Articles